TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02060162

Intervention type: OTHER
Intervention: Standard of care
Description: routine standard of care per Ministry of Health protocol including blood draws and examinations.

Intervention type: OTHER
Intervention: Standard of care
Description: routine standard of care per Ministry of Health protocol including blood draws and examinations.
Study: NCT04445649

Intervention type: DIAGNOSTIC_TEST
Intervention: Coma-Recovery-Scale-Revised (CRS-R)
Description: CRS-R assessments (15 minutes) are repeated weekly after study entry
Study: NCT00253539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arzoxifene hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arzoxifene hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02231372

Intervention type: DRUG
Intervention: Berodual® Respimat® solution for inhalation
Study: NCT01028521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: Solution for sc injection, single ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for sc injection
Study: NCT01874093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Ischemic Stroke System
Description: SPG stimulation and standard of care

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Sham stimulation and standard of care
Study: NCT02218489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121
Description: KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
Study: NCT03781713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KDIGO
Description: Interventions to prevent renal replacement therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delta SOFA
Description: interventions to improve SOFA score

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemia
Description: Interventions to prevent new episodes of hypoglycemia in the next 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug interaction risk D or X
Description: Intervention in the therapeutic plan in order to avoid adverse drug reactions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial stewardship
Description: Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
Study: NCT00002831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: IV over 4 hours on days -8 and -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given according to clinical grade of GVHD procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Infusion of stem cells on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Stem cell infusion on Day 0.
Study: NCT00988663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: patient will receive 5mg daily for 7day then 10 mgm daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: memantine
Description: patient will receive 5mg daily for 7day then 10 mgm daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will give placebo that looks like memantine
Study: NCT03816072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion
Description: Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion
Description: Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (\~0.1 Hz).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (\~0.1 Hz).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane
Study: NCT03331289

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide and Dapagliflozin
Description: Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
Study: NCT04741620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM (TRPV1 natural agonist)
Description: 10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM (TRPV1 natural agonist)
Description: 10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM (TRPV1 natural agonist)
Description: 10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM (TRPV1 natural agonist)
Description: 10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin 10microM (TRPV1 natural agonist)
Description: 10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Piperine 150microM (TRPV1 & TRPA1 natural agonist)
Description: 10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Piperine 150microM (TRPV1 & TRPA1 natural agonist)
Description: 10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Piperine 150microM (TRPV1 & TRPA1 natural agonist)
Description: 10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Piperine 150microM (TRPV1 & TRPA1 natural agonist)
Description: 10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Piperine 150microM (TRPV1 & TRPA1 natural agonist)
Description: 10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)
Description: 10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)
Description: 10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)
Description: 10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
Study: NCT03458169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapist LEAP session feedback
Description: A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participant LEAP session feedback
Description: A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LEAP risk control validation
Description: The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
Study: NCT04724889

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
Study: NCT02406157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-MPL
Description: Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 532-SLP
Description: Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
Study: NCT04130815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled furosemide
Description: 4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled furosemide
Description: 4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled furosemide
Description: 4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled furosemide
Description: 4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
Study: NCT01311778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
Study: NCT02013219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
Study: NCT02996786

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Danggui Buxue Tang
Description: Danggui Buxue Tang purchased from Kaiser Pharmaceutical
Study: NCT02013219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
Study: NCT02996786

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consisting of corn starch and carboxymethyl cellulose
Study: NCT02013219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
Study: NCT04741620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)
Description: 10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)
Description: 10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
Study: NCT01922297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day Treatment MDFT-HIV
Description: MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.

Intervention type: OTHER
Group type: OTHER
Intervention: Day Treatment SAU
Description: Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall \& Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
Study: NCT04741620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)
Description: 10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)
Description: 10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)
Description: 10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)
Description: 10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)
Description: 10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)
Description: 10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
Study: NCT02115698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy Resistance Training
Description: Supervised Heavy Resistance Training three times weekly for 52 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Intensity Training
Description: Home-based Light Intensity Training three-five times weekly for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Whey
Description: Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Whey
Description: Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Whey
Description: Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Collagen
Description: Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate
Description: Two daily 30 g carbohydrate supplementations for 52 weeks.
Study: NCT01334515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 fusion protein
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 fusion protein
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01311661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo twice daily
Description: Inhaled Placebo of Olodaterol twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol low daily dose twice daily
Description: Inhaled Olodaterol medium daily dose administered as low dose twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol medium daily dose twice daily
Description: Inhaled Olodaterol high daily dose administered as medium dose twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo twice daily
Description: Inhaled Placebo of Olodaterol twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol high daily dose once daily and placebo
Description: Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
Study: NCT04741620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)
Description: 10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)
Description: 10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)
Description: 10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.